Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies.

被引：0
作者：
Patel, Urvi
Oluwole, Olalekan O.
Kassim, Adetola
Jayani, Reena
Belliveau, Paul
Savani, Bipin
Dholaria, Bhagirathbhai R.
机构：
[1] Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[3] Massachusetts Coll Pharm & Hlth Sci, Worcester, MA USA
[4] Vanderbilt Ingram Canc Ctr, Div Hematol & Oncol, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20049
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
    Miller, Kevin
    Hashmi, Hamza
    Rajeeve, Sridevi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [42] Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma
    Melnekoff, David T.
    Ghodke-Puranik, Yogita
    Van Oekelen, Oliver
    Aleman, Adolfo
    Upadhyaya, Bhaskar
    Sebra, Robert
    Jagannath, Sundar
    Lagana, Alessandro
    Parekh, Samir
    BLOOD, 2021, 138
  • [43] Mezigdomide Enhances Activity of BCMA-Targeted Cellular and T-Cell Engager Therapies and Mitigates Immune Toxicity in Preclinical Models of Multiple Myeloma
    Larrayoz, Marta
    Bjorklund, Chad Chad
    Jimenez, Maddalen
    Lozano, Teresa
    Sanz, Sonia
    Arriazu, Elena
    Zon, Rebecca
    Rodriguez-Madoz, Juan Roberto
    Paiva, Bruno
    Rodriguez-Otero, Paula
    San-Miguel, Jesus
    Prosper, Felipe
    Jose Lasarte, Juan
    Ebert, Benjamin
    Hagner, Patrick
    Martinez-Climent, Jose Angel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S6 - S7
  • [44] Real-world comparison of overall survival between BCMA - bispecific and CAR-T therapies in multiple myeloma
    Song, J.
    Kim, G.
    Memon, R. S.
    Chi, K-Y.
    Chang, Y.
    Mehta, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S597 - S597
  • [45] Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.
    Graeter, Allison
    Alexis, Omar
    Puglianini, Castaneda
    Hansen, Doris K.
    Vazquez-Martinez, Mariola A.
    Blue, Brandon Jamaal
    Khadka, Sushmita
    Liu, Hien
    Ochoa-Bayona, Jose L.
    Freeman, Ciara L.
    Locke, Frederick L.
    Nishihori, Taiga
    Shain, Kenneth H.
    Baz, Rachid C.
    Alsina, Melissa
    Grajales-Cruz, Ariel Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
    Ferreri, Christopher J. J.
    Hildebrandt, Michelle A. T.
    Hashmi, Hamza
    Shune, Leyla O. O.
    McGuirk, Joseph P. P.
    Sborov, Douglas W. W.
    Wagner, Charlotte B. B.
    Kocoglu, M. Hakan
    Rapoport, Aaron
    Atrash, Shebli
    Voorhees, Peter M. M.
    Khouri, Jack
    Dima, Danai
    Afrough, Aimaz
    Kaur, Gurbakhash
    Anderson, Larry D. D.
    Simmons, Gary
    Davis, James A. A.
    Kalariya, Nilesh
    Peres, Lauren C. C.
    Lin, Yi
    Janakiram, Murali
    Nadeem, Omar
    Alsina, Melissa
    Locke, Frederick L. L.
    Sidana, Surbhi
    Hansen, Doris K. K.
    Patel, Krina K. K.
    Puglianini, Omar Alexis Castaneda
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [47] Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
    Christopher J. Ferreri
    Michelle A. T. Hildebrandt
    Hamza Hashmi
    Leyla O. Shune
    Joseph P. McGuirk
    Douglas W. Sborov
    Charlotte B. Wagner
    M. Hakan Kocoglu
    Aaron Rapoport
    Shebli Atrash
    Peter M. Voorhees
    Jack Khouri
    Danai Dima
    Aimaz Afrough
    Gurbakhash Kaur
    Larry D. Anderson
    Gary Simmons
    James A. Davis
    Nilesh Kalariya
    Lauren C. Peres
    Yi Lin
    Murali Janakiram
    Omar Nadeem
    Melissa Alsina
    Frederick L. Locke
    Surbhi Sidana
    Doris K. Hansen
    Krina K. Patel
    Omar Alexis Castaneda Puglianini
    Blood Cancer Journal, 13
  • [48] Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
    Gils Roex
    Marijke Timmers
    Kristien Wouters
    Diana Campillo-Davo
    Donovan Flumens
    Wilfried Schroyens
    Yiwei Chu
    Zwi N. Berneman
    Eva Lion
    Feifei Luo
    Sébastien Anguille
    Journal of Hematology & Oncology, 13
  • [49] Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
    Roex, Gils
    Timmers, Marijke
    Wouters, Kristien
    Campillo-Davo, Diana
    Flumens, Donovan
    Schroyens, Wilfried
    Chu, Yiwei
    Berneman, Zwi N.
    Lion, Eva
    Luo, Feifei
    Anguille, Sebastien
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [50] Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
    Sidana, Surbhi
    Hosoya, Hitomi
    Jensen, Alexandria
    Liu, Lawrence
    Goyal, Anmol
    Hovanky, Vanna
    Sahaf, Bita
    Bharadwaj, Sushma
    Latchford, Theresa
    Arai, Sally
    Leahy, Sheryl
    Mei, Matthew
    Budde, Lihua E.
    Muffly, Lori S.
    Frank, Matthew J.
    Dahiya, Saurabh
    Htut, Myo
    Miklos, David
    Janakiram, Murali
    BLOOD CANCER JOURNAL, 2023, 13 (01)
12345